sdBCMA2.28z

sdBCMA2.28z is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. The construct is distinguished by its use of a single-domain antibody (sdAb) binder derived from llamas, which was specifically selected for its dual reactivity to both human and murine BCMA. This dual-species reactivity enables the study of the therapy within immunocompetent syngeneic mouse models, such as the Vk*MYC model, allowing researchers to better understand the interactions between CAR-T cells and the complex tumor microenvironment. The CAR architecture includes a CD28 costimulatory domain and a CD3-zeta (CD3z) signaling domain to drive T-cell activation, proliferation, and cytotoxic activity upon binding to BCMA-positive cells. Preclinical data indicates that sdBCMA2.28z CAR-T cells exhibit robust anti-tumor efficacy, significant cytokine release (including IL-6 and TNF-alpha), and the ability to modulate the immune microenvironment by increasing M1-like macrophages.

Other names

sdBCMA2.CD28.CD3z CAR-TsdBCMA-2.CD28.CD3z CAR-TsdBCMA 2.CD28.CD3z CAR-T